Published by
The Street
The Street
By PR Newswire PHILADELPHIA, Dec. 20, 2021 /PRNewswire/ — Lannett Company, Inc. (LCI) – Get Lannett Company, Inc. Report today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC). “This IND submission is a key milestone and brings us one step closer to bringing this critically important and more affordable biosimilar medicine to the large and grow…